Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

84.78USD
16 Aug 2019
Change (% chg)

$0.84 (+1.00%)
Prev Close
$83.94
Open
$84.77
Day's High
$85.08
Day's Low
$84.27
Volume
1,618,713
Avg. Vol
1,480,788
52-wk High
$88.76
52-wk Low
$63.60

Latest Key Developments (Source: Significant Developments)

Abbott Laboratories Reports Q2 Gaap Earnings Per Share $0.56 From Continuing Operations
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS SECOND-QUARTER 2019 RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.82 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q2 GAAP EARNINGS PER SHARE $0.56 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE ESTIMATE $0.80 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.21 TO $3.27 FROM CONTINUING OPERATIONS.SEES Q3 ADJUSTED EARNINGS PER SHARE $0.83 TO $0.85 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q3 2019 GAAP EARNINGS PER SHARE $0.53 TO $0.55 FROM CONTINUING OPERATIONS.SEES FY 2019 GAAP EARNINGS PER SHARE $2.06 TO $2.12 FROM CONTINUING OPERATIONS.RAISING FULL-YEAR GUIDANCE FOR ORGANIC SALES GROWTH TO 7 TO 8 PERCENT.FY2019 EARNINGS PER SHARE VIEW $3.22 -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $0.85 -- REFINITIV IBES DATA.QTRLY SALES OF $ 7,979 MILLION VERSUS $ 7,767 MILLION REPORTED LAST YEAR.RAISING FULL-YEAR EPS FORECAST.FORECASTS SPECIFIED ITEMS FOR Q3 2019 OF $0.30 PER SHARE.FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.15 PER SHARE..QTRLY PEDIATRIC SALES $1,051 MILLION, UP 0.1% ON A REPORTED BASIS.FY2019 REVENUE VIEW $31.99 BILLION -- REFINITIV IBES DATA.SAYS "OUR SALES GROWTH ACCELERATED AND IS SUSTAINABLE".QTRLY TOTAL NUTRITION SALES $1,875 MILLION, UP 0.9% ON REPORTED BASIS.QTRLY TOTAL DIAGNOSTICS SALES $1,905 MILLION, UP 1.7% ON REPORTED BASIS.Q2 REVENUE VIEW $8.00 BILLION -- REFINITIV IBES DATA.SECOND-QUARTER WORLDWIDE SALES INCREASED 7.5 PERCENT ON AN ORGANIC BASIS.  Full Article

Abbott Announces FDA Approval Of Alinity s System
Thursday, 11 Jul 2019 

July 11 (Reuters) - Abbott Laboratories ::ABBOTT ANNOUNCES FDA APPROVAL OF THE ALINITY™ S SYSTEM, THE LATEST TECHNOLOGY FOR SCREENING AND PROTECTING THE U.S. BLOOD AND PLASMA SUPPLY.ABBOTT LABORATORIES - ALINITY™ S SYSTEM WILL SCREEN U.S. BLOOD AND PLASMA SUPPLY FASTER AND MORE EFFICIENTLY WHILE MAINTAINING HIGHEST LEVELS OF ACCURACY.  Full Article

Abbott Sets Quarterly Dividend Of $0.32 Per Share
Friday, 14 Jun 2019 

June 14 (Reuters) - Abbott Laboratories ::SETS QUARTERLY DIVIDEND OF $0.32 PER SHARE.  Full Article

Abbott Reports First Quarter GAAP Earnings Per Share Of $0.38 From Continuing Operations
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS FIRST-QUARTER 2019 RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.63 FROM CONTINUING OPERATIONS.Q1 GAAP EARNINGS PER SHARE $0.38 FROM CONTINUING OPERATIONS.Q1 EARNINGS PER SHARE ESTIMATE $0.61 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.15 TO $3.25 FROM CONTINUING OPERATIONS.SEES Q2 ADJUSTED EARNINGS PER SHARE $0.79 TO $0.81 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q2 2019 GAAP EARNINGS PER SHARE $0.47 TO $0.49 FROM CONTINUING OPERATIONS.SEES FY 2019 GAAP EARNINGS PER SHARE $1.95 TO $2.05 FROM CONTINUING OPERATIONS.QTRLY TOTAL PEDIATRIC SALES $1,029 MILLION VERSUS $994 MILLION REPORTED LAST YEAR.FIRST-QUARTER WORLDWIDE SALES OF $7.5 BILLION INCREASED 2.0 PERCENT ON A REPORTED BASIS AND 7.1 PERCENT ON AN ORGANIC BASIS.PROJECTS STRONG FULL-YEAR OUTLOOK.QTRLY TOTAL NUTRITION SALES $1,792 MILLION VERSUS $1,756 MILLION REPORTED LAST YEAR.QTRLY TOTAL DIAGNOSTICS SALES $1,841 MILLION VERSUS $1,837 MILLION REPORTED LAST YEAR.ABBOTT FORECASTS SPECIFIED ITEMS FOR Q2 2019 OF $0.32 PER SHARE.SAYS "WE'RE RIGHT ON TRACK WITH OUR EXPECTATIONS TO START THE YEAR".ABBOTT FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.20 PER SHARE.BOARD OF DIRECTORS OF ABBOTT DECLARED COMPANY'S QUARTERLY DIVIDEND OF $0.32 PER SHARE.SAYS "WE'RE TARGETING ANOTHER YEAR OF STRONG SALES AND EARNINGS GROWTH".Q1 REVENUE VIEW $7.47 BILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $0.80 -- REFINITIV IBES DATA.  Full Article

Abbott Announces CE Mark For Alinity M Diagnostics System And Assays
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Abbott Laboratories ::ABBOTT ANNOUNCES CE MARK FOR ALINITY™ M DIAGNOSTICS SYSTEM AND ASSAYS, THE LATEST IN MOLECULAR TECHNOLOGY, TO HELP DELIVER CRITICAL TEST RESULTS AND BENEFITS TO PATIENTS.  Full Article

Abbott Sets Quarterly Dividend Of $0.32 Per Share
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Abbott Laboratories ::SETS QUARTERLY DIVIDEND OF $0.32 PER SHARE.  Full Article

Abbott And Novo Nordisk Partner To Provide Integrated Digital Solution To People With Diabetes Using Insulin
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Abbott Laboratories ::ABBOTT AND NOVO NORDISK ENTER PARTNERSHIP TO PROVIDE INTEGRATED DIGITAL SOLUTION TO PEOPLE WITH DIABETES USING INSULIN.ABBOTT - PARTNERSHIP TO INTEGRATE INSULIN DOSE DATA FROM NOVO NORDISK CONNECTED PENS INTO DIGITAL HEALTH TOOLS COMPATIBLE WITH FREESTYLE LIBRE SYSTEM.  Full Article

Abbott Labs says Received CE Mark For Determine HBsAg 2 Test
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Abbott Laboratories ::RECEIVED CE MARK FOR DETERMINE HBSAG 2 TEST FOR USE WITH SERUM, PLASMA OR WHOLE BLOOD.  Full Article

Abbott Sees FY 2019 Earnings Per Share $1.80 To $1.90 From Continuing Operations
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS 2018 RESULTS AND ISSUES STRONG FORECAST FOR 2019.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.15 TO $3.25 FROM CONTINUING OPERATIONS.SEES Q1 ADJUSTED EARNINGS PER SHARE $0.60 TO $0.62 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2019 GAAP EARNINGS PER SHARE $1.80 TO $1.90 FROM CONTINUING OPERATIONS.SEES Q1 2019 GAAP EARNINGS PER SHARE $0.25 TO $0.27 FROM CONTINUING OPERATIONS.Q4 ADJUSTED EARNINGS PER SHARE $0.81 FROM CONTINUING OPERATIONS.Q4 GAAP EARNINGS PER SHARE $0.37 FROM CONTINUING OPERATIONS.Q4 EARNINGS PER SHARE ESTIMATE $0.81 -- REFINITIV IBES DATA.QTRLY TOTAL PEDIATRIC SALES $1,013 MILLION VERSUS $1,000 MILLION REPORTED LAST YEAR.QTRLY SALES OF $7.77 BILLION VERSUS $7.59 BILLION.Q4 REVENUE VIEW $7.82 BILLION -- REFINITIV IBES DATA.FOURTH-QUARTER WORLDWIDE SALES OF $7.8 BILLION INCREASED 2.3 PERCENT ON A REPORTED BASIS AND 6.4 PERCENT ON AN ORGANIC BASIS.ISSUING FULL-YEAR 2019 GUIDANCE FOR ORGANIC SALES GROWTH OF 6.5 TO 7.5 PERCENT.FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.35 PER SHARE.QTRLY TOTAL NUTRITION SALES OF $1,777 MILLION VERSUS $1,784 MILLION REPORTED LAST YEAR.FORECASTS SPECIFIED ITEMS FOR Q1 2019 OF $0.35 PER SHARE.FY2019 EARNINGS PER SHARE VIEW $3.20, REVENUE VIEW $32.15 BILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE VIEW $0.64 -- REFINITIV IBES DATA.QTRLY TOTAL DIAGNOSTICS SALES OF $1,961 MILLION VERSUS $1,906 MILLION REPORTED LAST YEAR.SAYS CO IS "VERY WELL-POSITIONED HEADING INTO 2019".  Full Article

Abbott To Acquire Cephea Valve Technologies, Inc.
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Abbott Laboratories ::ABBOTT TO ACQUIRE CEPHEA VALVE TECHNOLOGIES, INC..ABBOTT TO ACQUIRE CEPHEA VALVE TECHNOLOGIES, INC..ABBOTT LABORATORIES - FINANCIAL TERMS WERE NOT DISCLOSED.ABBOTT LABORATORIES - FINANCIAL TERMS WERE NOT DISCLOSED..ABBOTT LABORATORIES - EXERCISED OPTION TO BUY CEPHEA VALVE TECHNOLOGIES, A PRIVATELY HELD MEDICAL DEVICE CO.  Full Article

CORRECTED-Samsung Bioepis Humira biosimilar wins FDA approval

July 23 The U.S. Food and Drug Administration approved Samsung Bioepis Co Ltd's biosimilar to AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, the health agency said on Tuesday.